Search Results

Keywords: epidiolex

German group rejects CBD narcotic classification, wants sales only via prescription

September 3, 2020

An association of pharmacies dispensing medical cannabis in Germany spurned the idea that CBD ought to be considered a narcotic but wants the cannabinoid to remain available only via prescription. The German Association for Cannabis Dispensing Pharmacies said in a news release that “CBD is an important ingredient of the cannabis plant, which both influences the […]

Read More

High-dose CBD offers (potential) relief from cannabis use disorder

August 26, 2020 · Updated October 13, 2021

The first randomized clinical trial investigating the use of cannabidiol (CBD) to treat cannabis use disorder (CUD) has found CBD is safe and more effective at reducing problematic cannabis use than a placebo. Having a clinical treatment for CUD, which the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) defines as […]

Read More

FDA approves GW Pharmaceuticals’ cannabis drug for new indication

August 3, 2020

CBD drug Epidiolex received approval from the U.S. Food and Drug Administration to treat seizures associated with a third medical condition, expanding the range of indications for the cannabis-derived medication. The orally administered drug from Britain’s GW Pharmaceuticals previously was approved by the FDA to treat seizures associated with two forms of severe epilepsy, Lennox-Gastaut […]

Read More

Some WHO cannabis recommendations draw strong opposition at recent UN meeting

July 30, 2020

Two of the World Health Organization’s (WHO) cannabis scheduling recommendations might face an uphill battle getting adopted later this year by the United Nations’ Commission on Narcotic Drugs (CND). That revelation stems from an analysis of statements made by U.N.-member states at a recent two-day CND meeting. Still, many in the cannabis industry are hoping […]

Read More

UK down-schedules Epidyolex to lowest level for controlled drugs

June 24, 2020

The United Kingdom has down-scheduled Epidyolex to the lowest level of control for drugs, greatly easing restrictions on the cannabidiol medicine and reducing administrative processes for companies wanting to supply it. The U.K. said the new provisions – made through the Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2020 – came into force […]

Read More

England’s medical cannabis market shows little growth as of early 2020

May 14, 2020

England’s medical cannabis market has barely gotten off the ground since launching about 19 months ago, with a two-tier system in which few patients access products through legal channels while most resort to illicit suppliers. Looking ahead, however, some industry insiders are hopeful that recently implemented import rules could boost the number of legal medical cannabis prescriptions […]

Read More

GW Pharma trims loss to $8 million, warns virus could hit sales

May 12, 2020 · Updated August 7, 2020

GW Pharmaceuticals lost $8 million in its latest quarter – an improvement over the previous three-month period – but the United Kingdom-based medical cannabinoid company warned the COVID-19 pandemic could impact sales if fewer patients visit their doctors. Revenue in the quarter ending March 31 reached $120.6 million, up from $91 million and $109.1 million in […]

Read More

Week in Review: Cannabis firm iAnthus can’t make interest payments, MA gov sued, COVID-19 causes slide in adult-use marijuana sales & more

April 11, 2020 · Updated April 17, 2020

Multistate marijuana operator iAnthus defaulted on interest payments, in part blaming the coronavirus. In addition, the New York-based company revealed that its CEO is being investigated for a potential, but unidentified, conflict of interest. The company also postponed its financial results. MJBizDaily takeaway: COVID-19 aside, the disclosures from iAnthus are additional red flags for a company […]

Read More

New Zealand eases prescription requirement for cannabis-based medicine Sativex

April 9, 2020

Doctors in New Zealand no longer require Ministry of Health approval to prescribe Sativex, according to a new notice published in the country’s official Gazette – a move that could facilitate access to the pharmaceutical-grade, cannabis-based product. Any move to reduce bureaucratic-level processing of cannabinoid prescriptions is seen as a boon for patient access as well […]

Read More

Research Project

April 1, 2020 · Updated June 6, 2021

The U.S. Food and Drug Administration is approving a growing number of applications from cannabis companies looking to conduct clinical trials studying medical marijuana. That development could lead to multiple cannabis-based medicines—including flower—receiving FDA approval to be commercialized and sold within the next five years. While attitudes might be changing at the FDA, obtaining agency […]

Read More

GW Pharma beats projections with $108M in Q4 sales thanks to CBD drug

January 13, 2020

A popular cannabis-derived epilepsy treatment is increasing sales for a London company making pharmaceutical treatments from marijuana. London-based GW Pharmaceuticals told investors Monday that it rang up $108 million in sales last quarter and $309 million for calendar 2019. The company’s fourth-quarter sales beat consensus analyst expectations of $102.4 million. GW attributed the sales figures to physicians […]

Read More

England’s health insurance has covered only 18 ‘unlicensed’ cannabis prescriptions

November 19, 2019

Since a new law took effect a year ago, England’s National Health Service (NHS) has reimbursed patients on only 18 occasions for “unlicensed” cannabis-based products that have not undergone clinical trials, according to government data. In the case of private prescriptions – which are paid out of pocket by patients – the number of prescriptions reached 104. The data […]

Read More